TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02199041
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by intravenous infusion as part of the preparative regimen.
Study: NCT02199041
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by intravenous infusion as part of the preparative regimen.
Study: NCT02199041
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by intravenous infusion as part of the preparative regimen.
Study: NCT02199041
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Study: NCT02199041
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
Study: NCT02199041
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
Study: NCT02199041
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
Study: NCT02065232
Drug: Tilmanocept
Normalized name: tilmanocept
DrugBank: Tilmanocept (DB15373)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02065232
Drug: Sulfur Colloid
Normalized name: Sulfur Colloid
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03041935
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT03041935
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT00225251
Drug: bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant medication
Study: NCT03787251
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
Study: NCT00842686
Drug: bevacizumab, capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
Study: NCT00156533
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of Zolpidem
Study: NCT00156533
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04322253
Drug: Neladenoson bialanate (BAY 1067197)
Normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
Study: NCT01714154
Drug: danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg orally every 12 hours
Study: NCT01714154
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg orally every 12 hours
Study: NCT01714154
Drug: setrobuvir
Normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg orally every 12 hours
Study: NCT00249444
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine
Study: NCT01499667
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fingolimod 0.5 mg capsules for oral administration once daily
Study: NCT02673489
Drug: DCV
Normalized name: DCV
DrugBank: AV-COVID-19 (DB15802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02673489
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01918904
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
Study: NCT03041935
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT03041935
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT03041935
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See arm description
Study: NCT03041935
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT00947128
Drug: Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00947128
Drug: Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
Normalized name: ondansetron Oral Tablet [Zofran]
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01897532
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00087217
Drug: tanespimycin
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00243789
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day.
Study: NCT01870739
Drug: sacubitril/valsartan (LCZ696)
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg tablets
Study: NCT00087217
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00002429
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002429
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002429
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002429
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01870739
Drug: olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01870739
Drug: Amlodipine (Optional)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 15 mg twice daily, 28 days
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 50 mg twice daily, 28 days
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 150 mg twice daily, 28 days
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 300 mg twice daily, 28 days
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, dose TBD, twice daily, Cohort 5, 28 days
Study: NCT00122889
Drug: Garlic powder with high allicin content
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122889
Drug: Garlic powder with low allicin content
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122889
Drug: Garlic oil
Normalized name: Garlic Oil
DrugBank: Garlic oil (DB15989)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00122889
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03559270
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT04382443
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, dose TBD, twice daily, Cohort 6, 28 days
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, dose TBD, twice daily, Cohort 7, 28 days
Study: NCT03538743
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, dose TBD, twice daily, Cohort 8, 28 days
Study: NCT01978483
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01978483
Drug: Diphenylcyclopropenone
Normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04470388
Drug: EDP-514
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT03387956
Drug: Intrathecal atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100ug intrathecal atropine will be injected with spinal anesthesia
Study: NCT03387956
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous 8 mg dexamethasone (2ml).
Study: NCT03728933
Drug: Rotigotine 1 milligram/24 hours
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
Study: NCT03728933
Drug: Rotigotine 2 milligram/24 hours
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
Study: NCT01317992
Drug: Ibudilast
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
Study: NCT00582907
Drug: Rilonacept
Normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.2 mg/kg/wk by subcutaneous injection, for 3 months
Study: NCT02024412
Drug: monosialotetrahexosylganglioside Sodium
Normalized name: Monosialotetrahexosylganglioside
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: it is a component extract from pig's brain,shenjie is the brand name
Study: NCT00639457
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 30mg/day for 16 weeks
Study: NCT02403544
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
Study: NCT01015521
Drug: Aminoflavone Prodrug
Normalized name: amentoflavone
DrugBank: Flavone (DB07776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoflavone Prodrug administered D1, D8 of 21-day cycle
Study: NCT00370292
Drug: Pemetrexed - Before Protocol Amendment
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
Study: NCT00370292
Drug: Pemetrexed - After Protocol Amendment
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
Study: NCT00015847
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
Study: NCT02457026
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
Study: NCT02457026
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
Study: NCT02457026
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
Study: NCT00193024
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193024
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017043
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00186628
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
Study: NCT00186628
Drug: Anti-thymoglobulin, rabbit (ATG, rabbit ATG)
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
Study: NCT00186628
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates \> 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
Study: NCT00186628
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim provided as needed for neutrophil support
Study: NCT00186628
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
Study: NCT00186628
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
Study: NCT02581891
Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Normalized name: Eylea
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
Study: NCT02581891
Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Normalized name: Eylea
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
Study: NCT00000389
Drug: Fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01612676
Drug: FE 202158
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00089622
Drug: Lisuride Transdermal System
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02125344
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
Study: NCT02125344
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 80mg/m² 18 times weekly
Study: NCT02125344
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg/m² every 2 weeks for 3 cycles.
Study: NCT02125344
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
Study: NCT02125344
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
Study: NCT02125344
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
Study: NCT04375527
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02923154
Drug: MT-3995
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04344730
Drug: Dexamethasone injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
Study: NCT03383042
Drug: Cohort 2 (JP-1366 B mg)
Normalized name: 2-Hydroxypropyl-b-cyclodextrin
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT03383042
Drug: Cohort 4 (JP-1366 D mg)
Normalized name: 4-demethylepipodophyllotoxin β-D-ethylideneglucoside
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT03383042
Drug: Cohort 5 (JP-1366 E mg)
Normalized name: vitamin E 5 UNT
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT03383042
Drug: Cohort 9 (JP-1366 I mg)
Normalized name: C.I. basic blue 9
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
Study: NCT00848419
Drug: Epidural administration of bolus
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01130337
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2 intravenous infusion day 1 of every cycle
Study: NCT01130337
Drug: Trastuzumab [Herceptin]
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
Study: NCT00616642
Drug: rosiglitazone maleate
Normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03767439
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg PO daily
Study: NCT03767439
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480 mg IV every 4 weeks
Study: NCT03767439
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/kg IV every 6 weeks
Study: NCT04461353
Drug: Aerolized Hydroxychloroquine Sulfate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.